Physician profile
Robert William Hostoffer
NPI 1730159674
$23,728.68
in general payments reported to CMS, 2019-2025
59 companies · $4,183 in 2025
The $4,183 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,964 · 2020: $1,742 · 2021: $2,864 · 2022: $3,756 · 2023: $5,153 · 2024: $4,067 · 2025: $4,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $1,362 · Education: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,672.96 |
| Consulting Fee | $1,361.69 |
| Education | $368.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,318.39 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,513.68 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pharming Healthcare, INC. | $1,678.72 | 2019-2025 | Joenja, Ruconest |
| Csl Behring | $1,624.14 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $1,606.37 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,248.05 | 2020-2025 | Takhzyro, Hyqvia, Aralast |
| Genzyme Corporation | $1,131.31 | 2019-2025 | |
| Amgen INC. | $1,006.76 | 2019-2025 | Tezspire, Actimmune |
| Abbvie INC. | $913.55 | 2019-2024 | |
| Octapharma USA, INC. | $751.46 | 2021-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Regeneron Healthcare Solutions, INC. | $747.65 | 2019-2025 | Dupixent |
| Pfizer INC. | $736.99 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $673.61 | 2019-2023 | Airduo Digihaler |
| Optinose US, INC. | $615.52 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $604.51 | 2021-2025 | Orladeyo |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hostoffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.